Filing Flows › Regen BioPharma (RGBP) › Q4 FY24
Regen BioPharma (RGBP) Q4 FY24 earnings results (fourth quarter fiscal 2024)
10-K filed May 13, 2025
Regen BioPharma (RGBP) reported revenue of $59K for the fourth quarter fiscal 2024 (Q4 FY24) and +0.5% from the quarter before. Operating margin was -143.9%, net loss $66K (111.0% of revenue).
Regen BioPharma, Q4 FY24: revenue $59K, operating margin -143.9%, net loss $66K, operating cash flow −$207K. The chart follows the revenue to costs, profit and cash.
| Q4 FY24 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | +0.5% | — |
| Operating profit | −$85K | — | — |
| Net earnings | −$66K | — | — |
| Operating cash flow | −$207K | — | — |
What changed
Revenue was $59K in Q4 FY24, up 1% from the previous quarter.
Operating costs exceeded revenue by $85K, an operating margin of -143.9%. The quarter ended with a net loss of $66K, narrower than the previous quarter's $130K loss. Net interest and other expense of $185K was the main reason.
Operating cash flow was −$207K. Non-cash charges added back $11K of share-based compensation. Working capital and other items used $152K.
Questions
What was Regen BioPharma's revenue in the fourth quarter fiscal 2024?
Regen BioPharma (RGBP) reported revenue of $59K for the fourth quarter fiscal 2024 (Q4 FY24) and +0.5% from the quarter before.
Was Regen BioPharma profitable in the fourth quarter fiscal 2024?
Operating loss was $85K (-143.9% of revenue) and net loss $66K.
Source: Regen BioPharma 10-K on SEC EDGAR.